“Global Respiratory Inhalers market set to grow to $41bn by 2025” says new Visiongain report

28 January 2020
Pharma

Visiongain has launched a new pharma report The Global Respiratory Inhalers Market : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Respiratory inhalers are used to relieve the symptoms of asthma and COPD and prevent exacerbations, which can lead to expensive hospital stays for patients and increase the risk of mortality. The market is maturing with the launch of generic products expected during the forecast period. The launch of advanced products such as triple combination therapy and focus on development of e-devices are expected to drive the market growth.

Chekeh Mboge, the lead analyst of the report commented "Emerging countries will experience accelerated growth in the respiratory inhaler market, due to higher standards of living, rising life expectancy and an increase in urbanization. This demand alone will not mitigate falling revenues, and with generics becoming increasingly available due to past and upcoming patent expiry’s, traditional pharma companies are focusing on developing newer inhaler technology. These devices, which track patient usage and share with relevant HCPs, will tackle the huge unmet needs of patients: namely, lack of adherence and improper inhaler techniques. Digital inhalers will lead the way towards a patient pathway characterized by personalization and precision medicine. In addition to providing better health outcomes, these new digital inhalers will act as a high barrier to entry ceiling, to counter generic competition and will significantly drive growth in the market."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim, Chiesi, Farmaceutici S.p.A., GlaxoSmithKline (GSK), Merck & Co., Novartis, Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes European Antibiotics Market Report 2021-2031

Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.

22 June 2021

Read

Visiongain Publishes Companion Diagnostics (CDx) Market Report 2021-2031

Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.

17 June 2021

Read

Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.

15 June 2021

Read

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever